---
schema_version: "secwatch.filing_event.v1"
accession: "0001933414-24-000056"
form_type: "8-K"
ticker: "MLYS"
cik: "0001933414"
company_name: "Mineralys Therapeutics, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:18:58.933517+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Mineralys Q3 net loss widens to $56.3M; pivotal trial enrollments complete, data due H1 2025

## Summary
- Net loss of $56.3M for Q3 2024 vs $22.8M in Q3 2023; R&D expense rose to $54.0M from $22.5M.
- Cash & investments $263.6M; company believes sufficient to fund operations into 2026.
- Advance-HTN pivotal trial fully enrolled; topline data expected March 2025.
- Launch-HTN Phase 3 trial enrolled ahead of schedule; topline data anticipated mid first half 2025.
- Explore-CKD Phase 2 trial enrollment ongoing; topline data expected Q2 2025.

## SEC filing metadata
- accession: 0001933414-24-000056
- form_type: 8-K
- ticker: MLYS
- cik: 0001933414
- company_name: Mineralys Therapeutics, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1933414/000193341424000056/0001933414-24-000056-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1933414/000193341424000056/mlys-20241111.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001933414-24-000056
- JSON: https://secwatch.observer/filing/0001933414-24-000056.json
- Plain text: https://secwatch.observer/filing/0001933414-24-000056.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.